Related Experiment Video
Updated: May 18, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
[Endothelial dysfunction and apoptosis at early stage of chronic kidney disease]
Insights
Endothelial dysfunction and elevated endothelin-1 and annexin A5 levels are common in early chronic kidney disease (CKD). These factors independently impact endothelium-dependent vasodilation in CKD stages I-II.
Area of Science:
- Nephrology
- Cardiovascular Research
- Cell Biology
Context:
- Chronic kidney disease (CKD) affects endothelial function.
- Early stages of CKD (I-IIIb) exhibit significant changes.
- Endothelial dysfunction is a key factor in cardiovascular complications of CKD.
Purpose:
- To investigate changes in apoptosis and endothelial function in patients with CKD stages I-IIIb.
- To identify biomarkers associated with endothelial dysfunction in early CKD.
- To determine the impact of endothelin-1 and annexin A5 on endothelium-dependent vasodilation.
Summary:
- Reduced endothelium-dependent vasodilation (EDV) was observed in 34-70% of CKD patients across stages I-IIIb.
- Elevated endothelin-1 (ET-1) levels were found in 41-83% of CKD patients.
- Annexin A5 concentration significantly increased even in stage I CKD, correlating negatively with GFR.
Impact:
- Endothelin-1 and annexin A5 levels independently influence EDV in early CKD (stages I-II).
- Findings highlight potential therapeutic targets for preserving endothelial function in CKD.
- Early detection and management of endothelial dysfunction markers are crucial in CKD progression.
Aim:
To study changes in apoptosis and endothelial function in patients with chronic kidney disease (CKD) stage I-IIIb (CKDsI-IIIb).
Material And Methods:
A complex of biochemical, enzyme immunoassay and device investigations was used to examine 128 patients with CKDsI-IIIb.
Results:
In CKD stage I reduction of endothelium-dependent vasodilation (EDV) was detected in 34% patients, in stage II -- in 52 %, in stage IIIa -- y 52 %, in stage IIIb - in 70%. An EDV decrease was associated with glomerular filtration rate (GFR), a homocysteine level and hemodynamic factors. Elevation of endothelin-1 (ET-1) level was seen in CKDsI in 41 %, in CKDsII - in 54 %, in CKDsIIIa - in 70 %, in stage IIIb - in 83% patients. A negative correlation was observed between the level of ET-1 and GFR and positive - with diurnal proteinuria. A significant rise of annexin A5 concentration versus normal was detected as early as in CKDsI (1,14 +/- 0,68 ng/ml). In CKDsII annexin A5 was 2,61 +/- 0,75 ng/ml, in CKDsIIIa - 3,75 +/- 0,93 ng/ml and in CKDsIIIb - 5,16 +/- 1.01 ng/ml. Negative correlations were found between annexin A5 level and GFR, a maximal growth of volumetric blood flow rate in skin vessels in the acetylcholine test, positive correlations with systolic blood pressure, body mass index.
Conclusion:
The levels of ET-1 and annexin A5 are factors having an independent impact on EDV in patients with CKDsI-II.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Diabetic Nephropathy
Acute Kidney Injury II: Pathophysiology
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury I: Introduction